Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis

    Summary
    EudraCT number
    2019-003078-24
    Trial protocol
    Outside EU/EEA  
    Global end of trial date
    14 May 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    28 Nov 2024
    First version publication date
    28 Nov 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    R668-EE-1877
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04394351
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Regeneron Pharmaceuticals, Inc.
    Sponsor organisation address
    777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591
    Public contact
    Clinical Trials Administrator, Regeneron Pharmaceuticals, Inc., 001 844-734-6643, clinicaltrials@regeneron.com
    Scientific contact
    Clinical Trials Administrator, Regeneron Pharmaceuticals, Inc., 001 844-734-6643, clinicaltrials@regeneron.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    Yes
    EMA paediatric investigation plan number(s)
    EMEA-001501-PIP02-13
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    14 May 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    14 May 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The Primary objective is to demonstrate the efficacy of dupilumab treatment compared with placebo in pediatric participants with active eosinophilic esophagitis (EoE) based on histologic improvement meeting validated histologic criteria.
    Protection of trial subjects
    It is the responsibility of both the sponsor and the investigator(s) to ensure that this clinical study will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with the ICH guidelines for GCP and applicable regulatory requirements.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    01 Sep 2020
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Canada: 1
    Country: Number of subjects enrolled
    United States: 101
    Worldwide total number of subjects
    102
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    4
    Children (2-11 years)
    98
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    This study consisted of 3 parts: Part A (double-blind 16-week treatment period), Part B (36-week extended active treatment period) and Part C (open-label extension period of up to 108 weeks).

    Period 1
    Period 1 title
    Part A (16 weeks)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Investigator, Monitor, Carer, Data analyst, Assessor, Subject

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Part A: Pooled Placebo
    Arm description
    Participants who received subcutaneous (SC) injection of placebo matched to higher exposure dupilumab or lower exposure dupilumab in Part A. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W). Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance

    Arm title
    Part A: Dupilumab Low Dose
    Arm description
    Participants received subcutaneous (SC) injection of lower exposure dupilumab in Part A. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W)
    Arm type
    Experimental

    Investigational medicinal product name
    Dupilumab
    Investigational medicinal product code
    REGN668
    Other name
    SAR231893
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight

    Arm title
    Part A: Dupilumab High Dose
    Arm description
    Participants received subcutaneous (SC) injection of higher exposure dupilumab in Part A. Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW
    Arm type
    Experimental

    Investigational medicinal product name
    Dupilumab
    Investigational medicinal product code
    REGN668
    Other name
    SAR231893
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight

    Number of subjects in period 1
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Started
    34
    31
    37
    Completed
    33
    29
    37
    Not completed
    1
    2
    0
         Physician decision
    -
    1
    -
         Consent withdrawn by subject
    -
    1
    -
         Adverse event, non-fatal
    1
    -
    -
    Period 2
    Period 2 title
    Part B (36 weeks)
    Is this the baseline period?
    No
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Carer, Data analyst, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Part B: Placebo to Dupilumab Low Dose
    Arm description
    Participants who received subcutaneous (SC) injection of placebo in Part A and received lower exposure dupilumab in Part B. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W)
    Arm type
    Experimental

    Investigational medicinal product name
    Dupilumab
    Investigational medicinal product code
    REGN668
    Other name
    SAR231893
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight

    Arm title
    Part B: Placebo to Dupilumab High Dose
    Arm description
    Participants who received subcutaneous (SC) injection of placebo in Part A and received higher exposure dupilumab in Part B. Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW
    Arm type
    Experimental

    Investigational medicinal product name
    Dupilumab
    Investigational medicinal product code
    REGN668
    Other name
    SAR231893
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight

    Arm title
    Part B: Dupilumab Low Dose to Dupilumab Low Dose
    Arm description
    Participants received subcutaneous (SC) injection of lower exposure dupilumab in Parts A and B. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W)
    Arm type
    Experimental

    Investigational medicinal product name
    Dupilumab
    Investigational medicinal product code
    REGN668
    Other name
    SAR231893
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight

    Arm title
    Part B: Dupilumab High Dose to Dupilumab High Dose
    Arm description
    Participants received subcutaneous (SC) injection of higher exposure dupilumab in Parts A and B. Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW.
    Arm type
    Experimental

    Investigational medicinal product name
    Dupilumab
    Investigational medicinal product code
    REGN668
    Other name
    SAR231893
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight

    Number of subjects in period 2 [1]
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Started
    14
    18
    29
    37
    Completed
    14
    18
    29
    36
    Not completed
    0
    0
    0
    1
         Adverse event, non-fatal
    -
    -
    -
    1
    Notes
    [1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
    Justification: Part A participants transitioned to Part B
    Period 3
    Period 3 title
    Part C: Dupilumab (Up to Wk108+12Wk F/U)
    Is this the baseline period?
    No
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded
    Blinding implementation details
    Part C: Dupilumab (Up to Wk 108+12 Wk Follow-Up)

    Arms
    Arm title
    Part C: Dupilumab
    Arm description
    Participants who completed Part A and B were eligible to enroll in Part C and receive Dupilumab extended active treatment
    Arm type
    Experimental

    Investigational medicinal product name
    Dupilumab
    Investigational medicinal product code
    REGN668
    Other name
    SAR231893
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Part C consists of up to 108-week open-label extension period. All patients will receive higher exposure dupilumab subcutaneous (SC) administration at tiered dosing regimens based on body weight. No matching placebo administered in Part C.

    Number of subjects in period 3 [2]
    Part C: Dupilumab
    Started
    61
    Completed
    8
    Not completed
    53
         Physician decision
    3
         Consent withdrawn by subject
    16
         Other
    32
         Protocol deviation
    2
    Notes
    [2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
    Justification: Part B participants transitioned to Part C

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Part A: Pooled Placebo
    Reporting group description
    Participants who received subcutaneous (SC) injection of placebo matched to higher exposure dupilumab or lower exposure dupilumab in Part A. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W). Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW.

    Reporting group title
    Part A: Dupilumab Low Dose
    Reporting group description
    Participants received subcutaneous (SC) injection of lower exposure dupilumab in Part A. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W)

    Reporting group title
    Part A: Dupilumab High Dose
    Reporting group description
    Participants received subcutaneous (SC) injection of higher exposure dupilumab in Part A. Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW

    Reporting group values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose Total
    Number of subjects
    34 31 37 102
    Age categorical
    Units: Subjects
        In utero
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
        Newborns (0-27 days)
    0
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    0
        Adults (18-64 years)
    0
        From 65-84 years
    0
        85 years and over
    0
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    7.2 ( 3.03 ) 7.2 ( 3.07 ) 6.8 ( 3.11 ) -
    Sex: Female, Male
    Units: participants
        Female
    9 6 9 24
        Male
    25 25 28 78
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    3 2 2 7
        Not Hispanic or Latino
    30 29 33 92
        Unknown or Not Reported
    1 0 2 3
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    0 0 0 0
        Asian
    0 1 1 2
        Native Hawaiian or Other Pacific Islander
    0 0 0 0
        Black or African American
    3 4 4 11
        White
    30 22 32 84
        More than one race
    0 0 0 0
        Unknown or Not Reported
    0 0 0 0
        Other
    1 4 0 5

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Part A: Pooled Placebo
    Reporting group description
    Participants who received subcutaneous (SC) injection of placebo matched to higher exposure dupilumab or lower exposure dupilumab in Part A. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W). Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW.

    Reporting group title
    Part A: Dupilumab Low Dose
    Reporting group description
    Participants received subcutaneous (SC) injection of lower exposure dupilumab in Part A. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W)

    Reporting group title
    Part A: Dupilumab High Dose
    Reporting group description
    Participants received subcutaneous (SC) injection of higher exposure dupilumab in Part A. Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW
    Reporting group title
    Part B: Placebo to Dupilumab Low Dose
    Reporting group description
    Participants who received subcutaneous (SC) injection of placebo in Part A and received lower exposure dupilumab in Part B. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W)

    Reporting group title
    Part B: Placebo to Dupilumab High Dose
    Reporting group description
    Participants who received subcutaneous (SC) injection of placebo in Part A and received higher exposure dupilumab in Part B. Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW

    Reporting group title
    Part B: Dupilumab Low Dose to Dupilumab Low Dose
    Reporting group description
    Participants received subcutaneous (SC) injection of lower exposure dupilumab in Parts A and B. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W)

    Reporting group title
    Part B: Dupilumab High Dose to Dupilumab High Dose
    Reporting group description
    Participants received subcutaneous (SC) injection of higher exposure dupilumab in Parts A and B. Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW.
    Reporting group title
    Part C: Dupilumab
    Reporting group description
    Participants who completed Part A and B were eligible to enroll in Part C and receive Dupilumab extended active treatment

    Subject analysis set title
    Part A: Pooled Placebo
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who received subcutaneous (SC) injection of placebo matched to higher exposure dupilumab or lower exposure dupilumab in Part A. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W). Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW.

    Subject analysis set title
    Part A: Dupilumab Low Dose
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants received subcutaneous (SC) injection of lower exposure dupilumab in Part A. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W

    Subject analysis set title
    Part A: Dupilumab High Dose
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants received subcutaneous (SC) injection of higher exposure dupilumab in Part A. Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW

    Subject analysis set title
    Part B: Placebo to Dupilumab Low Dose
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who received subcutaneous (SC) injection of placebo in Part A and received lower exposure dupilumab in Part B. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W

    Subject analysis set title
    Part B: Placebo to Dupilumab High Dose
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who received subcutaneous (SC) injection of placebo in Part A and received higher exposure dupilumab in Part B. Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW

    Subject analysis set title
    Part B: Dupilumab Low Dose to Dupilumab Low Dose
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants received subcutaneous (SC) injection of lower exposure dupilumab in Parts A and B. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W

    Subject analysis set title
    Part B: Dupilumab High Dose to Dupilumab High Dose
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants received subcutaneous (SC) injection of higher exposure dupilumab in Parts A and B. Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW.

    Subject analysis set title
    Part C: Dupilumab
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who completed Part A or B were eligible to enroll in Part C and receive Dupilumab extended active treatment

    Subject analysis set title
    Part C: Dupilumab
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Participants received Dupilumab; Anti-Drug Antibody Analysis Set (AAS): The Part C AAS included all participants who received any amount of study drug in Part C and had at least 1 non-missing ADA result following the first dose of study drug. Analysis was based on treatment received.

    Primary: Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of Less Than or Equal to (≤) 6 Eosinophils/High Power Field (eos/hpf) at Week 16

    Close Top of page
    End point title
    Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of Less Than or Equal to (≤) 6 Eosinophils/High Power Field (eos/hpf) at Week 16
    End point description
    Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available. Analysis was performed on Part A FAS which included all randomized participants in Part A.
    End point type
    Primary
    End point timeframe
    At Week 16
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    34
    31
    37
    Units: percentage of participants
        number (confidence interval 95%)
    2.9 (0.07 to 15.33)
    58.1 (39.08 to 75.45)
    67.6 (50.21 to 81.99)
    Statistical analysis title
    A: Dupilumab Low Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab Low Dose
    Number of subjects included in analysis
    65
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001
    Method
    Cochran-Mantel-Haenszel
    Parameter type
    Odds ratio (OR)
    Point estimate
    46.7
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    5.47
         upper limit
    399.54
    Statistical analysis title
    A: Dupilumab High Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab High Dose
    Number of subjects included in analysis
    71
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001
    Method
    Cochran-Mantel-Haenszel
    Parameter type
    Odds ratio (OR)
    Point estimate
    53.8
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    7.37
         upper limit
    392.82

    Secondary: Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 16

    Close Top of page
    End point title
    Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 16
    End point description
    Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.
    End point type
    Secondary
    End point timeframe
    At Week 16
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    34
    31
    37
    Units: percentage of participants
        number (confidence interval 95%)
    2.9 (0.07 to 15.33)
    67.7 (48.63 to 83.32)
    83.8 (67.99 to 93.81)
    Statistical analysis title
    A: Dupilumab Low Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab Low Dose
    Number of subjects included in analysis
    65
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001 [1]
    Method
    Cochran-Mantel-Haenszel
    Parameter type
    Odds ratio (OR)
    Point estimate
    55.3
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    7.45
         upper limit
    410.23
    Notes
    [1] - P-value is not adjusted for multiple comparisons
    Statistical analysis title
    A: Dupilumab High Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab High Dose
    Number of subjects included in analysis
    71
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001
    Method
    Cochran-Mantel-Haenszel
    Parameter type
    Odds ratio (OR)
    Point estimate
    178
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    18.84
         upper limit
    1682.4

    Secondary: Part A: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 16

    Close Top of page
    End point title
    Part A: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 16
    End point description
    Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available. Least squared (LS) mean and standard error (SE) from analysis of covariance (ANCOVA) model with Baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    34
    31
    37
    Units: percent change
        least squares mean (standard error)
    20.98 ( 12.23 )
    -77.93 ( 12.89 )
    -86.09 ( 11.84 )
    Statistical analysis title
    A: Dupilumab Low Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab Low Dose
    Number of subjects included in analysis
    65
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001 [2]
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    -98.92
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -132.463
         upper limit
    -65.37
    Notes
    [2] - P-value is not adjusted for multiple comparisons
    Statistical analysis title
    A: Dupilumab High Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab High Dose
    Number of subjects included in analysis
    71
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    -107.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -139.249
         upper limit
    -74.9

    Secondary: Part A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 16

    Close Top of page
    End point title
    Part A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 16
    End point description
    EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity & extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean grade scores summed over the 3 regions was the final score used in primary analysis, the mean grade score ranged from 0 to 3, with higher score indicating more severe.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    34
    31
    37
    Units: Score on a scale
        least squares mean (standard error)
    0.023 ( 0.0498 )
    -0.757 ( 0.0524 )
    -0.879 ( 0.0481 )
    Statistical analysis title
    A: Dupilumab High Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab High Dose
    Number of subjects included in analysis
    71
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    -0.902
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.0325
         upper limit
    -0.7714
    Statistical analysis title
    A: Dupilumab Low Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab Low Dose
    Number of subjects included in analysis
    65
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001 [3]
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    -0.78
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.917
         upper limit
    -0.644
    Notes
    [3] - P-value is not adjusted for multiple comparisons

    Secondary: Part A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 16

    Close Top of page
    End point title
    Part A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 16
    End point description
    EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity & extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean stage scores summed over the 3 regions was the final score used in primary analysis, the mean stage score ranged from 0 to 3, with higher score indicating more severe.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    34
    31
    37
    Units: Score on a scale
        least squares mean (standard error)
    0.048 ( 0.0482 )
    -0.721 ( 0.0507 )
    -0.835 ( 0.0466 )
    Statistical analysis title
    A: Dupilumab Low Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab Low Dose
    Number of subjects included in analysis
    65
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001 [4]
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    -0.769
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.9013
         upper limit
    -0.6362
    Notes
    [4] - P-value is not adjusted for multiple comparisons
    Statistical analysis title
    A: Dupilumab High Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab High Dose
    Number of subjects included in analysis
    71
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    -0.883
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.0095
         upper limit
    -0.7568

    Secondary: Part A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 16

    Close Top of page
    End point title
    Part A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 16
    End point description
    A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for T2INF reflect the expression at Week 16 relative to Baseline of the pre-specified gene set as a way to evaluate normalization of type 2 inflammation with treatment. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have a minimum/maximum score. Analysis was performed on Part A FAS which included all randomized participants in Part A. Here, 'overall number of participants analyzed' = participants with available data for this outcome measure.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    21
    15
    24
    Units: Score on a scale
        median (full range (min-max))
    0.340 (-1.84 to 1.65)
    -1.930 (-2.00 to -1.39)
    -1.895 (-2.03 to -1.61)
    Statistical analysis title
    A: Dupilumab Low Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab Low Dose
    Number of subjects included in analysis
    36
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001 [5]
    Method
    Wilcoxon rank-sum test
    Parameter type
    Hodges-Lehmann estimator
    Point estimate
    -2.19
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.45
         upper limit
    -1.82
    Notes
    [5] - P-value is not adjusted for multiple comparisons
    Statistical analysis title
    A: Dupilumab High Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab High Dose
    Number of subjects included in analysis
    45
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001
    Method
    Wilcoxon rank-sum test
    Parameter type
    Hodges-Lehmann estimator
    Point estimate
    -2.22
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.44
         upper limit
    -1.95

    Secondary: Part A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Eosinophilic Esophagitis (EoE) Diagnostic Panel (EDP) at Week 16

    Close Top of page
    End point title
    Part A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Eosinophilic Esophagitis (EoE) Diagnostic Panel (EDP) at Week 16
    End point description
    A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at Week 16 relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score. Analysis was performed on Part A FAS which included all randomized participants in Part A. Here, 'overall number of participants analyzed' = participants with available data for this outcome measure.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    21
    15
    24
    Units: Score on a scale
        median (full range (min-max))
    0.180 (-2.53 to 2.39)
    -2.710 (-2.84 to -0.80)
    -2.630 (-2.85 to -2.25)
    Statistical analysis title
    A: Dupilumab Low Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab Low Dose
    Number of subjects included in analysis
    36
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001 [6]
    Method
    Wilcoxon rank-sum test
    Parameter type
    Hodges-Lehmann estimator
    Point estimate
    -2.7
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.31
         upper limit
    -1.62
    Notes
    [6] - P-value is not adjusted for multiple comparisons
    Statistical analysis title
    A: Dupilumab High Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab High Dose
    Number of subjects included in analysis
    45
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001
    Method
    Wilcoxon rank-sum test
    Parameter type
    Hodges-Lehmann estimator
    Point estimate
    -2.84
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.35
         upper limit
    -1.96

    Secondary: Part A: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 16

    Close Top of page
    End point title
    Part A: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 16
    End point description
    The EoE-EREFS is a validated endoscopic scoring system for inflammatory and remodeling features of EoE including edema, rings, exudates, furrows, and stricture. The score was assessed in the proximal and distal esophageal regions with each region scored from 0 to 9 with total scores ranging from 0 to 18. Higher scores indicate worse endoscopic inflammatory and remodeling findings.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    34
    31
    37
    Units: score on a scale
        least squares mean (standard error)
    0.3 ( 0.45 )
    -3.0 ( 0.48 )
    -3.5 ( 0.42 )
    Statistical analysis title
    A: Dupilumab Low Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab Low Dose
    Number of subjects included in analysis
    65
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001 [7]
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    -3.3
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -4.59
         upper limit
    -2.1
    Notes
    [7] - P-value is not adjusted for multiple comparisons
    Statistical analysis title
    A: Dupilumab High Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab High Dose
    Number of subjects included in analysis
    71
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    -3.8
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -4.94
         upper limit
    -2.63

    Secondary: Part A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs as Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 16 (for Participants Aged ≥1 to <12 Years)

    Close Top of page
    End point title
    Part A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs as Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 16 (for Participants Aged ≥1 to <12 Years)
    End point description
    PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. PESQ-C measures the signs of EoE observed by the caregiver, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    34
    31
    37
    Units: proportion of days
        least squares mean (standard error)
    -0.17 ( 0.054 )
    -0.18 ( 0.060 )
    -0.28 ( 0.052 )
    Statistical analysis title
    A: Dupilumab Low Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab Low Dose
    Number of subjects included in analysis
    65
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.9533 [8]
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    0
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.155
         upper limit
    0.146
    Notes
    [8] - P-value is not adjusted for multiple comparisons
    Statistical analysis title
    A: Dupilumab High Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab High Dose
    Number of subjects included in analysis
    71
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.1526
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    -0.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.244
         upper limit
    0.038

    Secondary: Part A: Number of Sign-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-C (for participants aged ≥1 to <12 years)

    Close Top of page
    End point title
    Part A: Number of Sign-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-C (for participants aged ≥1 to <12 years)
    End point description
    PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. The PESQ-C measures the signs of EoE observed by the caregiver, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food. WOCF approach was used for imputing the missing data due to rescue treatment/AE/lack of efficacy, and the multiple imputations approach was used for the missing data due to other reasons. LS mean SE derived from ANCOVA model.
    End point type
    Secondary
    End point timeframe
    Week 16
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    34
    31
    37
    Units: sign-free days
        least squares mean (standard error)
    8.93 ( 0.756 )
    8.93 ( 0.840 )
    10.38 ( 0.735 )
    Statistical analysis title
    A: Dupilumab Low Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab Low Dose
    Number of subjects included in analysis
    65
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.9965 [9]
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    0
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.107
         upper limit
    2.117
    Notes
    [9] - P-value is not adjusted for multiple comparisons
    Statistical analysis title
    A: Dupilumab High Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab High Dose
    Number of subjects included in analysis
    71
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.1507 [10]
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    1.45
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.527
         upper limit
    3.422
    Notes
    [10] - P-value is not adjusted for multiple comparisons

    Secondary: Part A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 16

    Close Top of page
    End point title
    Part A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 16
    End point description
    PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. The PESQ-C measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    34
    31
    37
    Units: proportion of segments
        least squares mean (standard error)
    -0.11 ( 0.032 )
    -0.09 ( 0.036 )
    -0.16 ( 0.031 )
    Statistical analysis title
    A: Dupilumab Low Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab Low Dose
    Number of subjects included in analysis
    65
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.6361 [11]
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    0.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.069
         upper limit
    0.112
    Notes
    [11] - P-value is not adjusted for multiple comparisons
    Statistical analysis title
    A: Dupilumab High Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab High Dose
    Number of subjects included in analysis
    71
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.2064 [12]
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    -0.05
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.139
         upper limit
    0.03
    Notes
    [12] - P-value is not adjusted for multiple comparisons

    Secondary: Part A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for participants aged ≥8 to <12 years) at Week 16

    Close Top of page
    End point title
    Part A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for participants aged ≥8 to <12 years) at Week 16
    End point description
    The PESQ-P was a participant-reported outcome measure intended to be completed independently by participants ≥8 to <12 years of age. The PESQ-P measured occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    17
    19
    17
    Units: proportion of days
        least squares mean (standard error)
    -0.26 ( 0.068 )
    -0.16 ( 0.067 )
    -0.13 ( 0.077 )
    Statistical analysis title
    A: Dupilumab Low Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab Low Dose
    Number of subjects included in analysis
    36
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.2975 [13]
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    0.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.088
         upper limit
    0.286
    Notes
    [13] - P-value is not adjusted for multiple comparisons
    Statistical analysis title
    A: Dupilumab High Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab High Dose
    Number of subjects included in analysis
    34
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.2086 [14]
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    0.13
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.072
         upper limit
    0.33
    Notes
    [14] - P-value is not adjusted for multiple comparisons

    Secondary: Part A: Number of Symptom-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years)

    Close Top of page
    End point title
    Part A: Number of Symptom-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years)
    End point description
    The PESQ-P was a participant-reported outcome measure intended to be completed independently by EoE participants ≥8 to <12 years of age. The PESQ-P measures the signs of EoE, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food. The PESQ-P score was calculated based on the daily responses over a 14-day period (i.e., the 14 days prior to the baseline visit and the week 16 visit). The score ranges from 0 to 1. WOCF approach was used for imputing the missing data due to rescue treatment/AE/lack of efficacy, and the multiple imputations approach was used for the missing data due to other reasons. LS Mean SE from ANCOVA.
    End point type
    Secondary
    End point timeframe
    Week 16
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    17
    19
    17
    Units: sign-free days
        least squares mean (standard error)
    10.49 ( 0.953 )
    9.13 ( 0.936 )
    8.69 ( 1.081 )
    Statistical analysis title
    A: Dupilumab Low Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab Low Dose
    Number of subjects included in analysis
    36
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.3098 [15]
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    -1.36
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.972
         upper limit
    1.26
    Notes
    [15] - P-value is not adjusted for multiple comparisons
    Statistical analysis title
    A: Dupilumab High Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab High Dose
    Number of subjects included in analysis
    34
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.2085 [16]
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    -1.8
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -4.615
         upper limit
    1.007
    Notes
    [16] - P-value is not adjusted for multiple comparisons

    Secondary: Part A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 16

    Close Top of page
    End point title
    Part A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 16
    End point description
    The PESQ-P was a participant-reported outcome measure intended to be completed independently by EoE participants ≥8 to <12 years of age. The PESQ-P measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    17
    19
    17
    Units: proportion of segments
        least squares mean (standard error)
    -0.15 ( 0.040 )
    -0.08 ( 0.039 )
    -0.08 ( 0.045 )
    Statistical analysis title
    A: Dupilumab Low Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab Low Dose
    Number of subjects included in analysis
    36
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.1939 [17]
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    0.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.037
         upper limit
    0.181
    Notes
    [17] - P-value is not adjusted for multiple comparisons
    Statistical analysis title
    A: Dupilumab High Dose vs A: Pooled Placebo
    Comparison groups
    Part A: Pooled Placebo v Part A: Dupilumab High Dose
    Number of subjects included in analysis
    34
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.236 [18]
    Method
    ANCOVA
    Parameter type
    LS mean difference
    Point estimate
    0.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.046
         upper limit
    0.186
    Notes
    [18] - P-value is not adjusted for multiple comparisons

    Secondary: Part A: Change From Baseline in Total Score as Measured by the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) Version 2.0 Caregiver Version (PEESSv2.0-C) at Week 16

    Close Top of page
    End point title
    Part A: Change From Baseline in Total Score as Measured by the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) Version 2.0 Caregiver Version (PEESSv2.0-C) at Week 16
    End point description
    The PEESSv2.0-C is a caregiver-reported outcome measure that assesses the frequency and severity of EoE symptoms among pediatric participants. The PEESSv2.0-C consists of 20 items and has a one-month recall period. Each item had a 0-4 scale, which was transformed to 0-100 as follows: 0 = 0, 1 = 25, 2 = 50, 3 = 75, 4 = 100. The mean total PEESSv2.0 score was computed as the sum of all the item scores over the number of items answered. The total PEESSv2.0-C score ranges from 0 to 100 where higher scores indicate greater symptom burden among pediatric EoE participants. Values after first rescue treatment use were set to missing (censoring). WOCF approach was used for imputing the missing data due to rescue treatment/AE/lack of efficacy, and the MI approach was used for the missing data due to other reasons. LS mean SE from ANCOVA model.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    34
    31
    37
    Units: score on a scale
        least squares mean (standard error)
    -11.83 ( 2.909 )
    -10.10 ( 2.785 )
    -19.86 ( 2.577 )
    No statistical analyses for this end point

    Secondary: Part A: Concentration of Functional Dupilumab in Serum at Baseline, Week 4 and 16

    Close Top of page
    End point title
    Part A: Concentration of Functional Dupilumab in Serum at Baseline, Week 4 and 16 [19]
    End point description
    Concentration of functional dupilumab in serum at Baseline, Week 4 and 16 was reported in this outcome measure.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 4 and 16
    Notes
    [19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only participants who received dupilumab were included in the analysis of this endpoint.
    End point values
    Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    28
    36
    Units: milligrams per liter (mg/L)
    arithmetic mean (standard deviation)
        Baseline
    0 ( 0 )
    0 ( 0 )
        Week 4
    40.6 ( 11.2 )
    75.7 ( 25.7 )
        Week 16
    86.0 ( 29.2 )
    163 ( 60.8 )
    No statistical analyses for this end point

    Secondary: Part B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils/High Power Field at Week 52

    Close Top of page
    End point title
    Part B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils/High Power Field at Week 52
    End point description
    Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.
    End point type
    Secondary
    End point timeframe
    At Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    14
    17
    29
    35
    Units: percentage of participants
        number (not applicable)
    92.9
    52.9
    65.5
    62.9
    No statistical analyses for this end point

    Secondary: Part B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 52

    Close Top of page
    End point title
    Part B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 52
    End point description
    Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.
    End point type
    Secondary
    End point timeframe
    At Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    14
    17
    29
    35
    Units: percentage of participants
        number (not applicable)
    92.9
    64.7
    69.0
    85.7
    No statistical analyses for this end point

    Secondary: Part B: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 52

    Close Top of page
    End point title
    Part B: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 52
    End point description
    Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    14
    17
    29
    35
    Units: percent change
        arithmetic mean (standard deviation)
    -92.72 ( 19.229 )
    -76.83 ( 41.228 )
    -85.41 ( 22.851 )
    -90.97 ( 14.482 )
    No statistical analyses for this end point

    Secondary: Part B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 52

    Close Top of page
    End point title
    Part B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 52
    End point description
    EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity & extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean grade scores summed over the 3 regions was the final score used in primary analysis, the mean grade score ranged from 0 to 3, with higher score indicating more severe.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    14
    17
    29
    35
    Units: Score on a scale
        arithmetic mean (standard deviation)
    -0.804 ( 0.3099 )
    -0.885 ( 0.2962 )
    -0.773 ( 0.3374 )
    -0.967 ( 0.3920 )
    No statistical analyses for this end point

    Secondary: Part B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 52

    Close Top of page
    End point title
    Part B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 52
    End point description
    EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity & extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean stage scores summed over the 3 regions was the final score used in primary analysis, the mean stage score ranged from 0 to 3, with higher score indicating more severe.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    14
    17
    29
    35
    Units: Score on a scale
        arithmetic mean (standard deviation)
    -0.767 ( 0.3114 )
    -0.855 ( 0.3485 )
    -0.784 ( 0.3183 )
    -0.892 ( 0.3181 )
    No statistical analyses for this end point

    Secondary: Part B: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 52

    Close Top of page
    End point title
    Part B: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 52
    End point description
    The EoE-EREFS is a validated endoscopic scoring system for inflammatory and remodeling features of EoE including edema, rings, exudates, furrows, and stricture. The score was assessed in the proximal and distal esophageal regions with each region scored from 0 to 9 with total scores possibly ranging from 0 to 18. Higher scores indicate worse endoscopic inflammatory and remodeling findings.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    11
    14
    22
    30
    Units: score on a scale
        arithmetic mean (standard deviation)
    -5.82 ( 1.722 )
    -3.64 ( 3.342 )
    -4.50 ( 3.203 )
    -4.77 ( 3.081 )
    No statistical analyses for this end point

    Secondary: Part B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 52

    Close Top of page
    End point title
    Part B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 52
    End point description
    PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    6
    9
    18
    27
    Units: proportion of days
        arithmetic mean (standard deviation)
    -0.20 ( 0.373 )
    -0.47 ( 0.395 )
    -0.49 ( 0.339 )
    -0.30 ( 0.299 )
    No statistical analyses for this end point

    Secondary: Part B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 52

    Close Top of page
    End point title
    Part B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 52
    End point description
    PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. The PESQ-C measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    6
    9
    18
    27
    Units: proportion of segments
        arithmetic mean (standard deviation)
    -0.03 ( 0.249 )
    -0.24 ( 0.221 )
    -0.26 ( 0.250 )
    -0.17 ( 0.187 )
    No statistical analyses for this end point

    Secondary: Part B: Number of Sign-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-C (for Participants Aged ≥1 to <12 Years)

    Close Top of page
    End point title
    Part B: Number of Sign-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-C (for Participants Aged ≥1 to <12 Years)
    End point description
    PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study.
    End point type
    Secondary
    End point timeframe
    Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    6
    9
    18
    27
    Units: sign-free days
        arithmetic mean (standard deviation)
    11.58 ( 3.968 )
    12.10 ( 4.652 )
    11.35 ( 3.947 )
    12.13 ( 4.053 )
    No statistical analyses for this end point

    Secondary: Part B: Number of Symptom-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years)

    Close Top of page
    End point title
    Part B: Number of Symptom-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years)
    End point description
    The PESQ-P was a participant-reported outcome measure intended to be completed independently by participants ≥8 to <12 years of age. The PESQ-P measures the signs of EoE, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food.
    End point type
    Secondary
    End point timeframe
    Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    3
    6
    11
    12
    Units: sign-free days
        arithmetic mean (standard deviation)
    9.33 ( 8.083 )
    11.67 ( 5.715 )
    10.64 ( 4.943 )
    13.63 ( 0.874 )
    No statistical analyses for this end point

    Secondary: Part B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for Participants Aged ≥8 to <12 Years) at Week 52

    Close Top of page
    End point title
    Part B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for Participants Aged ≥8 to <12 Years) at Week 52
    End point description
    The PESQ-P was a participant-reported outcome measure intended to be completed independently by participants ≥8 to <12 years of age. The PESQ-P measured occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    3
    6
    11
    12
    Units: proportion of days
        arithmetic mean (standard deviation)
    -0.33 ( 0.322 )
    -0.43 ( 0.369 )
    -0.42 ( 0.400 )
    -0.26 ( 0.396 )
    No statistical analyses for this end point

    Secondary: Part B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 52

    Close Top of page
    End point title
    Part B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 52
    End point description
    The PESQ-P was a participant-reported outcome measure intended to be completed independently by EoE participants ≥8 to <12 years of age. The PESQ-P measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    3
    6
    11
    12
    Units: proportion of segments
        arithmetic mean (standard deviation)
    -0.17 ( 0.164 )
    -0.26 ( 0.269 )
    -0.21 ( 0.293 )
    -0.16 ( 0.284 )
    No statistical analyses for this end point

    Secondary: Part B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the EoE Diagnostic Panel (EDP) at Week 52

    Close Top of page
    End point title
    Part B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the EoE Diagnostic Panel (EDP) at Week 52
    End point description
    A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at Week 16 relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    8
    12
    16
    21
    Units: NES
        number (not applicable)
    -2.715
    -2.615
    -2.625
    -2.670
    No statistical analyses for this end point

    Secondary: Part B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 52

    Close Top of page
    End point title
    Part B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 52
    End point description
    A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for T2INF reflect the expression at Week 16 relative to Baseline of the pre-specified gene set as a way to evaluate normalization of type 2 inflammation with treatment. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score. Analysis was performed on Part B SAF which included all participants who received at least 1 dose of Part B study drug. Here, 'overall number of participants analyzed' = participants with available data for this outcome measure
    End point type
    Secondary
    End point timeframe
    Baseline, Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    8
    12
    16
    21
    Units: Score on a scale
        median (inter-quartile range (Q1-Q3))
    -1.960 (-2.000 to -1.895)
    -1.965 (-1.995 to -1.765)
    -1.920 (-1.965 to -1.865)
    -1.920 (-1.930 to -1.850)
    No statistical analyses for this end point

    Secondary: Part B: Change From Baseline in Body Weight for Age Percentile at Week 52

    Close Top of page
    End point title
    Part B: Change From Baseline in Body Weight for Age Percentile at Week 52
    End point description
    Body weight for age percentile was calculated based on the growth charts from the Centers for Disease Control and Prevention (CDC) for ages 0 to 20 years (for ages 2 to <12 years) and World Health Organization (WHO) growth charts for ages 0 to <2 years (for ages 1 to <2 years). These charts included a set of smoothed percentiles along with CDC LMS (Lambda-Mu-Sigma) parameters to allow the calculation of percentiles.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    14
    16
    29
    35
    Units: Percentile
        arithmetic mean (standard deviation)
    -0.02 ( 13.893 )
    5.48 ( 12.644 )
    4.75 ( 11.968 )
    5.96 ( 11.519 )
    No statistical analyses for this end point

    Secondary: Part B: Change from Baseline in Body Mass Index (BMI) for Age Z-score for Participants ≥2 Years of Age at Week 52

    Close Top of page
    End point title
    Part B: Change from Baseline in Body Mass Index (BMI) for Age Z-score for Participants ≥2 Years of Age at Week 52
    End point description
    BMI for age z-score indicates how much higher or lower a participant’s BMI for age is relative to a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention [CDC] for ages 0 to 20 years [for ages 2 to <12 years]). An increase in the mean change in BMI for age z-score (ie, increase in the standard deviation [SD] from the reference growth chart) indicates an increase in BMI for age relative to the reference.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    14
    15
    27
    32
    Units: z-score
        arithmetic mean (standard deviation)
    -0.0206 ( 0.54625 )
    0.0687 ( 0.47605 )
    -0.0549 ( 0.88582 )
    0.0987 ( 0.72329 )
    No statistical analyses for this end point

    Secondary: Part B: Change From Baseline in Weight for Age Z-score at Week 52

    Close Top of page
    End point title
    Part B: Change From Baseline in Weight for Age Z-score at Week 52
    End point description
    Weight for age z-score indicates how much higher or lower a participant’s weight for age is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years [for ages 2 to <12 years] and World Health Organization (WHO) growth charts for ages 0 to <2 years [for ages 1 to <2 years]). An increase in the mean change in weight for age z-score (increase in the SD from the reference growth chart) indicates an increase in weight for age relative to the reference.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    14
    16
    29
    35
    Units: z-score
        arithmetic mean (standard deviation)
    0.0640 ( 0.46264 )
    0.2016 ( 0.39446 )
    0.1445 ( 0.40310 )
    0.2049 ( 0.40305 )
    No statistical analyses for this end point

    Secondary: Part B: Change From Baseline in Body Weight From Height Z-score at Week 52

    Close Top of page
    End point title
    Part B: Change From Baseline in Body Weight From Height Z-score at Week 52
    End point description
    Weight for height z-score indicates how much higher or lower a participant’s weight for height is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years [for ages 2 to <12 years] and WHO growth charts for ages 0 to <2 years [for ages 1 to <2 years]). An increase in the mean change in weight for height z-score (increase in the SD from the reference growth chart) indicates an increase in weight for height relative to the reference.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    2
    3
    9
    12
    Units: z-score
        arithmetic mean (standard deviation)
    0.0962 ( 0.48902 )
    -0.0100 ( 0.51706 )
    -0.2700 ( 1.04895 )
    -0.0151 ( 0.67968 )
    No statistical analyses for this end point

    Secondary: Part B: Concentration of Functional Dupilumab in Serum at Week 32 and 52

    Close Top of page
    End point title
    Part B: Concentration of Functional Dupilumab in Serum at Week 32 and 52
    End point description
    Concentration of functional dupilumab in serum at Week 32 and 52 was reported in this outcome measure.
    End point type
    Secondary
    End point timeframe
    Week 32 and 52
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    14
    18
    29
    37
    Units: mg/L
    arithmetic mean (standard deviation)
        Week 32
    105 ( 49.8 )
    142 ( 48.5 )
    99.0 ( 42.8 )
    186 ( 59.5 )
        Week 52
    101 ( 44.3 )
    149 ( 59.1 )
    83.0 ( 33.2 )
    179 ( 75.3 )
    No statistical analyses for this end point

    Secondary: Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Adverse Events of Special Interest (AESIs) and TEAEs Leading to Permanent Discontinuation of Study Drug

    Close Top of page
    End point title
    Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Adverse Events of Special Interest (AESIs) and TEAEs Leading to Permanent Discontinuation of Study Drug
    End point description
    An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation patient administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious AE was any untoward medical occurrence that at any dose resulted in death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or a medically important event. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. An AESI was defined as one of scientific and medical concern specific to the Sponsor’s product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate.
    End point type
    Secondary
    End point timeframe
    From Baseline up to Week 16 in Part A
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    34
    30
    37
    Units: Participants
        Participants with any TEAE
    31
    26
    27
        Participants with any Serious TEAE
    0
    1
    2
        Participants with any AESI
    1
    1
    2
        Any TEAE leading to discontinuation of study drug
    2
    0
    0
    No statistical analyses for this end point

    Secondary: Part B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Adverse Events of Special Interest (AESIs) and TEAEs Leading to Permanent Discontinuation of Study Drug

    Close Top of page
    End point title
    Part B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Adverse Events of Special Interest (AESIs) and TEAEs Leading to Permanent Discontinuation of Study Drug
    End point description
    An AE was defined as any untoward medical occurrence in a participant or clinical investigation patient administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious AE was any untoward medical occurrence that at any dose resulted in death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or a medically important event. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. An AESI was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate.
    End point type
    Secondary
    End point timeframe
    From Week 16 up to Week 52 in Part B
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    14
    18
    29
    37
    Units: Participants
        Participants with any TEAE
    14
    15
    28
    34
        Participants with any Serious TEAE
    1
    0
    3
    2
        Participants with any AESI
    0
    1
    3
    4
        Any TEAE leading to discontinuation of study drug
    0
    0
    0
    1
    No statistical analyses for this end point

    Secondary: Part A: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response

    Close Top of page
    End point title
    Part A: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response
    End point description
    Treatment-emergent ADA was defined as a negative result or missing result at baseline with at least one positive post baseline result in the ADA assay. Samples positive in the dupilumab ADA assay were characterized for ADA titers (low, moderate and high). The low treatment-emergent ADA titer as defined as titer level <1000, moderate as 1000 to 10000 and high as >10000.
    End point type
    Secondary
    End point timeframe
    From Baseline up to Week 16 in Part A
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    25
    26
    31
    Units: Participants
    1
    0
    1
    No statistical analyses for this end point

    Secondary: Part A: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) by Maximum Titer Category

    Close Top of page
    End point title
    Part A: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) by Maximum Titer Category
    End point description
    Treatment-emergent ADA was defined as a negative result or missing result at baseline with at least one positive post baseline result in the ADA assay. Samples positive in the dupilumab ADA assay were characterized for ADA titers (low, moderate and high). The low treatment-emergent ADA titer as defined as titer level <1000, moderate as 1000 to 10000 and high as >10000.
    End point type
    Secondary
    End point timeframe
    From Baseline up to Week 16 in Part A
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    1
    0 [20]
    1
    Units: Participants
        Treatment-emergent ADA Titer: Low
    1
    1
        Treatment-emergent ADA Titer: Moderate
    0
    0
        Treatment-emergent ADA Titer: High
    0
    0
    Notes
    [20] - Number of participants analyzed of 0 = none had positive TE ADA response to measure titer level.
    No statistical analyses for this end point

    Secondary: Part B: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response and Titer

    Close Top of page
    End point title
    Part B: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response and Titer
    End point description
    Treatment-emergent ADA was defined as a negative result or missing result at baseline with at least one positive post baseline result in the ADA assay. Samples positive in the dupilumab ADA assay were characterized for ADA titers (low, moderate and high). The low treatment-emergent ADA titer as defined as titer level <1000, moderate as 1000 to 10000 and high as >10000. No patient exhibited a treatment-emergent ADA response in Part B and titer was not reported.
    End point type
    Secondary
    End point timeframe
    From Week 16 up to Week 52 in Part B
    End point values
    Part B: Placebo to Dupilumab Low Dose Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose
    Number of subjects analysed
    14
    18
    29
    37
    Units: Participants
    0
    0
    0
    0
    No statistical analyses for this end point

    Secondary: Part C: Percentage of participants achieving peak esophageal intraepithelial eosinophil count of <15 eos/hpf At Week 160

    Close Top of page
    End point title
    Part C: Percentage of participants achieving peak esophageal intraepithelial eosinophil count of <15 eos/hpf At Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    At Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    0 [21]
    Units: Percentage
        number (not applicable)
    Notes
    [21] - No data was collected for this endpoint.
    No statistical analyses for this end point

    Secondary: Part C: Percentage of participants achieving peak esophageal intraepithelial eosinophil count of <15 eos/hpf At Week 100

    Close Top of page
    End point title
    Part C: Percentage of participants achieving peak esophageal intraepithelial eosinophil count of <15 eos/hpf At Week 100
    End point description
    End point type
    Secondary
    End point timeframe
    At Week 100
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    41
    Units: Percentage of participants
        number (not applicable)
    92.7
    No statistical analyses for this end point

    Secondary: Part C: Percentage of participants achieving peak esophageal intraepithelial eosinophil count of ≤6 eos/hpf (400×) at Week 160

    Close Top of page
    End point title
    Part C: Percentage of participants achieving peak esophageal intraepithelial eosinophil count of ≤6 eos/hpf (400×) at Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    At Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    0 [22]
    Units: Percentage of participants
        number (not applicable)
    Notes
    [22] - No data was collected for this endpoint
    No statistical analyses for this end point

    Secondary: Part C: Percentage of participants achieving peak esophageal intraepithelial eosinophil count of ≤6 eos/hpf (400×) At Week 100

    Close Top of page
    End point title
    Part C: Percentage of participants achieving peak esophageal intraepithelial eosinophil count of ≤6 eos/hpf (400×) At Week 100
    End point description
    End point type
    Secondary
    End point timeframe
    At Week 100
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    41
    Units: Percentage of participants
        number (not applicable)
    70.7
    No statistical analyses for this end point

    Secondary: Part C: Percent change in peak esophageal intraepithelial eosinophil count (eos/hpf) from Baseline to Week 100

    Close Top of page
    End point title
    Part C: Percent change in peak esophageal intraepithelial eosinophil count (eos/hpf) from Baseline to Week 100
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to Week 100
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    41
    Units: Percentage of change
        arithmetic mean (standard deviation)
    -91.50 ( 13.348 )
    No statistical analyses for this end point

    Secondary: Part C: Absolute change in mean EoE-HSS from Baseline to Week 100

    Close Top of page
    End point title
    Part C: Absolute change in mean EoE-HSS from Baseline to Week 100
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to Week 100
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    61
    Units: Score on a scale
    arithmetic mean (standard deviation)
        EoE-HSS Grade Score
    1.213 ( 0.3720 )
        EoE-HSS Stage Score
    1.232 ( 0.3526 )
    No statistical analyses for this end point

    Secondary: Part C: Percent change in peak esophageal intraepithelial eosinophil count (eos/hpf) from Baseline to Week 160

    Close Top of page
    End point title
    Part C: Percent change in peak esophageal intraepithelial eosinophil count (eos/hpf) from Baseline to Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    0 [23]
    Units: Percentage of change
        number (not applicable)
    Notes
    [23] - No data was collected for this endpoint.
    No statistical analyses for this end point

    Secondary: Part C: Absolute change in EoE-EREFS from Baseline to Week 100

    Close Top of page
    End point title
    Part C: Absolute change in EoE-EREFS from Baseline to Week 100
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to Week 100
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    32
    Units: Score on a scale
        arithmetic mean (standard deviation)
    -5.34 ( 2.535 )
    No statistical analyses for this end point

    Secondary: Part C: Absolute change in mean EoE-HSS from Baseline to Week 160

    Close Top of page
    End point title
    Part C: Absolute change in mean EoE-HSS from Baseline to Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    0 [24]
    Units: Score on a scale
        arithmetic mean (standard deviation)
    ( )
    Notes
    [24] - No data was collected for this endpoint.
    No statistical analyses for this end point

    Secondary: Part C: Absolute change in EoE-EREFS from Baseline to Week 160

    Close Top of page
    End point title
    Part C: Absolute change in EoE-EREFS from Baseline to Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    0 [25]
    Units: Score on a scale
        arithmetic mean (standard deviation)
    ( )
    Notes
    [25] - No data was collected for this endpoint.
    No statistical analyses for this end point

    Secondary: Part C: Change in total score as measured by the PEESSv2.0- caregiver version questionnaire from Baseline to Week 160

    Close Top of page
    End point title
    Part C: Change in total score as measured by the PEESSv2.0- caregiver version questionnaire from Baseline to Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    0 [26]
    Units: Score on a scale
        number (not applicable)
    Notes
    [26] - No data was collected for this endpoint.
    No statistical analyses for this end point

    Secondary: Part C: NES for the relative change in the EDP transcriptome signature from Baseline to Week 100

    Close Top of page
    End point title
    Part C: NES for the relative change in the EDP transcriptome signature from Baseline to Week 100
    End point description
    A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at Week 16 relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.
    End point type
    Secondary
    End point timeframe
    Baseline to Week 100
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    39
    Units: Score on a scale
        median (inter-quartile range (Q1-Q3))
    -2.720 (-2.800 to -2.510)
    No statistical analyses for this end point

    Secondary: Part C: NES for the relative change in the EDP transcriptome signature from Baseline to Week 160

    Close Top of page
    End point title
    Part C: NES for the relative change in the EDP transcriptome signature from Baseline to Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    0 [27]
    Units: Score on a scale
        number (not applicable)
    Notes
    [27] - No data collected for this endpoint
    No statistical analyses for this end point

    Secondary: Part C: NES for the relative change in the type 2 inflammation transcriptome signature Baseline to Week 100

    Close Top of page
    End point title
    Part C: NES for the relative change in the type 2 inflammation transcriptome signature Baseline to Week 100
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to Week 100
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    39
    Units: Score on a scale
        number (not applicable)
    -1.970
    No statistical analyses for this end point

    Secondary: Part C: Change in body weight for age percentile from Baseline up to Week 160

    Close Top of page
    End point title
    Part C: Change in body weight for age percentile from Baseline up to Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    0 [28]
    Units: kilograms (kg)
        number (not applicable)
    Notes
    [28] - No data was collected for this endpoint
    No statistical analyses for this end point

    Secondary: Part C: NES for the relative change in the type 2 inflammation transcriptome signature from Baseline to Week 160

    Close Top of page
    End point title
    Part C: NES for the relative change in the type 2 inflammation transcriptome signature from Baseline to Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    0 [29]
    Units: Score on a scale
        number (not applicable)
    Notes
    [29] - No data was collected for this endpoint
    No statistical analyses for this end point

    Secondary: Part C: Change in body mass index for age z-score from Baseline to up to Week 160

    Close Top of page
    End point title
    Part C: Change in body mass index for age z-score from Baseline to up to Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to up to Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    0 [30]
    Units: z-score
        arithmetic mean (standard deviation)
    ( )
    Notes
    [30] - No data was collected for this endpoint
    No statistical analyses for this end point

    Secondary: Part C: Incidence of TEAEs Up to Week 160

    Close Top of page
    End point title
    Part C: Incidence of TEAEs Up to Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Up to Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    61
    Units: Events
        number (not applicable)
    86.9
    No statistical analyses for this end point

    Secondary: Part C: Percentage of participants (with food elimination diet regimens at baseline) that have a re-introduction of a previously eliminated food group from Baseline by Week 160

    Close Top of page
    End point title
    Part C: Percentage of participants (with food elimination diet regimens at baseline) that have a re-introduction of a previously eliminated food group from Baseline by Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline by Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    0 [31]
    Units: Percentage of participants
        number (not applicable)
    Notes
    [31] - No data was collected for this endpoint
    No statistical analyses for this end point

    Secondary: Part C: Percentage of participants (with food elimination diet regimens at baseline) that have a re-introduction of a previously eliminated food group from Baseline by Week 100

    Close Top of page
    End point title
    Part C: Percentage of participants (with food elimination diet regimens at baseline) that have a re-introduction of a previously eliminated food group from Baseline by Week 100
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline by Week 100
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    61
    Units: Percentage of participants
        number (not applicable)
    14.8
    No statistical analyses for this end point

    Secondary: Part C: Change in weight for height z-score from Baseline up to Week 160

    Close Top of page
    End point title
    Part C: Change in weight for height z-score from Baseline up to Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    0 [32]
    Units: z-score
        arithmetic mean (standard deviation)
    ( )
    Notes
    [32] - No data was collected for this endpoint
    No statistical analyses for this end point

    Secondary: Part C: Change in weight for age z-score from Baseline up to Week 160

    Close Top of page
    End point title
    Part C: Change in weight for age z-score from Baseline up to Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    0 [33]
    Units: z-score
        arithmetic mean (standard deviation)
    ( )
    Notes
    [33] - No data was collected for this endpoint
    No statistical analyses for this end point

    Secondary: Part C: Number of Participants with treatment-emergent ADA responses and titer Up to Week 160

    Close Top of page
    End point title
    Part C: Number of Participants with treatment-emergent ADA responses and titer Up to Week 160
    End point description
    Anti-Drug Antibody Analysis Set (AAS): The Part C AAS included all participants who received any amount of study drug in Part C and had at least 1 non-missing ADA result following the first dose of study drug. Analysis was based on treatment received.
    End point type
    Secondary
    End point timeframe
    Up to Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    39
    Units: Participants
        number (not applicable)
    0
    No statistical analyses for this end point

    Secondary: Part C: Incidence of treatment-emergent AESIs Up to Week 160

    Close Top of page
    End point title
    Part C: Incidence of treatment-emergent AESIs Up to Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Up to Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    61
    Units: Events
        number (not applicable)
    9.8
    No statistical analyses for this end point

    Secondary: Part C: Incidence of treatment-emergent SAEs Up to Week 160

    Close Top of page
    End point title
    Part C: Incidence of treatment-emergent SAEs Up to Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Up to Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    61
    Units: Events
        number (not applicable)
    4.9
    No statistical analyses for this end point

    Secondary: Part C: Incidence of TEAEs leading to permanent discontinuation of study treatment Up to Week 160

    Close Top of page
    End point title
    Part C: Incidence of TEAEs leading to permanent discontinuation of study treatment Up to Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Up to Week 160
    End point values
    Part C: Dupilumab
    Number of subjects analysed
    61
    Units: Events
        number (not applicable)
    0
    No statistical analyses for this end point

    Secondary: Part C: Concentration of functional dupilumab in serum up to Week 160

    Close Top of page
    End point title
    Part C: Concentration of functional dupilumab in serum up to Week 160
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to end of study, Up to Week 160
    End point values
    Part A: Pooled Placebo Part A: Dupilumab Low Dose Part A: Dupilumab High Dose
    Number of subjects analysed
    0 [34]
    0 [35]
    0 [36]
    Units: mg/L
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    Notes
    [34] - No data was collected for this endpoint
    [35] - No data was collected for this endpoint
    [36] - No data was collected for this endpoint
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From signing of the informed consent through week 160 + 12 week follow-up
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    27.0
    Reporting groups
    Reporting group title
    Part A: Pooled Placebo
    Reporting group description
    Participants who received subcutaneous (SC) injection of placebo matched to higher exposure dupilumab or lower exposure dupilumab in Part A. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W). Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW.

    Reporting group title
    Part A: Dupilumab High Dose
    Reporting group description
    Participants received subcutaneous (SC) injection of higher exposure dupilumab in Part A. Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW

    Reporting group title
    Part C: Dupilumab
    Reporting group description
    Participants who completed Part A or B were eligible to enroll in Part C and receive Dupilumab extended active treatment

    Reporting group title
    Part B: Placebo to Dupilumab High Dose
    Reporting group description
    Participants who received subcutaneous (SC) injection of placebo in Part A and received higher exposure dupilumab in Part B. Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW

    Reporting group title
    Part B: Dupilumab Low Dose to Dupilumab Low Dose
    Reporting group description
    Participants received subcutaneous (SC) injection of lower exposure dupilumab in Parts A and B. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W

    Reporting group title
    Part B: Dupilumab High Dose to Dupilumab High Dose
    Reporting group description
    Participants received subcutaneous (SC) injection of higher exposure dupilumab in Parts A and B. Higher exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab QW.

    Reporting group title
    Part A: Dupilumab Low Dose
    Reporting group description
    Participants received subcutaneous (SC) injection of lower exposure dupilumab in Part A. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W

    Reporting group title
    Part B: Placebo to Dupilumab Low Dose
    Reporting group description
    Participants who received subcutaneous (SC) injection of placebo in Part A and received lower exposure dupilumab in Part B. Lower exposure dupilumab regimen were exposures approximating those in adolescents and adults receiving 300 mg dupilumab Q2W

    Serious adverse events
    Part A: Pooled Placebo Part A: Dupilumab High Dose Part C: Dupilumab Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose Part A: Dupilumab Low Dose Part B: Placebo to Dupilumab Low Dose
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 34 (0.00%)
    2 / 37 (5.41%)
    3 / 61 (4.92%)
    0 / 18 (0.00%)
    2 / 29 (6.90%)
    2 / 37 (5.41%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         number of deaths (all causes)
    0
    0
    0
    0
    0
    0
    0
    0
         number of deaths resulting from adverse events
    Investigations
    Endoscopy gastrointestinal
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Procedural pain
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Post procedural haemorrhage
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Cardiac arrest
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Leukocytosis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Oesophageal food impaction
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Sleep apnoea syndrome
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Throat tightness
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    1 / 29 (3.45%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Obstructive sleep apnoea syndrome
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Asthma
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Nephrolithiasis
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    HCoV-OC43 infection
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    1 / 29 (3.45%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Perirectal abscess
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Part A: Pooled Placebo Part A: Dupilumab High Dose Part C: Dupilumab Part B: Placebo to Dupilumab High Dose Part B: Dupilumab Low Dose to Dupilumab Low Dose Part B: Dupilumab High Dose to Dupilumab High Dose Part A: Dupilumab Low Dose Part B: Placebo to Dupilumab Low Dose
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    28 / 34 (82.35%)
    26 / 37 (70.27%)
    52 / 61 (85.25%)
    16 / 18 (88.89%)
    27 / 29 (93.10%)
    31 / 37 (83.78%)
    24 / 30 (80.00%)
    14 / 14 (100.00%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Skin papilloma
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    1
    0
    0
    Vascular disorders
    Flushing
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    General disorders and administration site conditions
    Injection site reaction
         subjects affected / exposed
    7 / 34 (20.59%)
    4 / 37 (10.81%)
    5 / 61 (8.20%)
    5 / 18 (27.78%)
    4 / 29 (13.79%)
    5 / 37 (13.51%)
    4 / 30 (13.33%)
    4 / 14 (28.57%)
         occurrences all number
    8
    11
    32
    21
    17
    18
    11
    34
    Injection site erythema
         subjects affected / exposed
    1 / 34 (2.94%)
    4 / 37 (10.81%)
    2 / 61 (3.28%)
    2 / 18 (11.11%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    1 / 30 (3.33%)
    1 / 14 (7.14%)
         occurrences all number
    1
    8
    2
    2
    0
    0
    2
    1
    Pyrexia
         subjects affected / exposed
    1 / 34 (2.94%)
    2 / 37 (5.41%)
    11 / 61 (18.03%)
    2 / 18 (11.11%)
    3 / 29 (10.34%)
    6 / 37 (16.22%)
    0 / 30 (0.00%)
    3 / 14 (21.43%)
         occurrences all number
    1
    2
    18
    4
    3
    7
    0
    3
    Fatigue
         subjects affected / exposed
    0 / 34 (0.00%)
    2 / 37 (5.41%)
    0 / 61 (0.00%)
    3 / 18 (16.67%)
    1 / 29 (3.45%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    2
    0
    3
    1
    0
    0
    0
    Injection site pain
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    3 / 61 (4.92%)
    1 / 18 (5.56%)
    1 / 29 (3.45%)
    1 / 37 (2.70%)
    3 / 30 (10.00%)
    3 / 14 (21.43%)
         occurrences all number
    0
    0
    5
    1
    3
    1
    3
    6
    Injection site haemorrhage
         subjects affected / exposed
    1 / 34 (2.94%)
    1 / 37 (2.70%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    2 / 37 (5.41%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    1
    1
    2
    0
    0
    2
    0
    1
    Injection site swelling
         subjects affected / exposed
    1 / 34 (2.94%)
    1 / 37 (2.70%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    2 / 37 (5.41%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    1
    1
    0
    0
    0
    2
    0
    1
    Chest pain
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    3 / 37 (8.11%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    3
    0
    0
    Malaise
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    0
    Injection site induration
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Injection site inflammation
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    2 / 29 (6.90%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    4
    1
    0
    0
    Injection site oedema
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    1 / 61 (1.64%)
    1 / 18 (5.56%)
    1 / 29 (3.45%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    4
    1
    1
    1
    1
    0
    0
    Influenza like illness
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    1 / 30 (3.33%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    1
    Vessel puncture site pain
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Injection site mass
         subjects affected / exposed
    1 / 34 (2.94%)
    1 / 37 (2.70%)
    2 / 61 (3.28%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    1
    11
    0
    0
    2
    0
    0
    Injection site bruising
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    1
    0
    0
    0
    0
    0
    Immune system disorders
    Seasonal allergy
         subjects affected / exposed
    2 / 34 (5.88%)
    0 / 37 (0.00%)
    4 / 61 (6.56%)
    1 / 18 (5.56%)
    4 / 29 (13.79%)
    2 / 37 (5.41%)
    1 / 30 (3.33%)
    1 / 14 (7.14%)
         occurrences all number
    2
    0
    5
    1
    4
    2
    1
    1
    Food allergy
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    2 / 61 (3.28%)
    2 / 18 (11.11%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    2
    2
    0
    1
    0
    0
    Immunisation reaction
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    1 / 29 (3.45%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    1
    0
    0
    0
    Anaphylactic reaction
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    2 / 29 (6.90%)
    0 / 37 (0.00%)
    1 / 30 (3.33%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    1
    0
    2
    0
    1
    0
    Reproductive system and breast disorders
    Genital rash
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Genital pain
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    2 / 34 (5.88%)
    1 / 37 (2.70%)
    8 / 61 (13.11%)
    5 / 18 (27.78%)
    4 / 29 (13.79%)
    5 / 37 (13.51%)
    2 / 30 (6.67%)
    1 / 14 (7.14%)
         occurrences all number
    2
    2
    11
    7
    4
    6
    2
    1
    Rhinitis allergic
         subjects affected / exposed
    3 / 34 (8.82%)
    1 / 37 (2.70%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    3 / 29 (10.34%)
    2 / 37 (5.41%)
    2 / 30 (6.67%)
    0 / 14 (0.00%)
         occurrences all number
    3
    1
    0
    0
    4
    2
    2
    0
    Asthma
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    2 / 61 (3.28%)
    0 / 18 (0.00%)
    5 / 29 (17.24%)
    3 / 37 (8.11%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    1
    0
    2
    0
    6
    3
    0
    1
    Oropharyngeal pain
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    6 / 61 (9.84%)
    2 / 18 (11.11%)
    1 / 29 (3.45%)
    2 / 37 (5.41%)
    1 / 30 (3.33%)
    2 / 14 (14.29%)
         occurrences all number
    1
    0
    6
    2
    1
    3
    1
    2
    Epistaxis
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    3 / 61 (4.92%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    1
    4
    2
    0
    2
    0
    1
    Wheezing
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Bronchial hyperreactivity
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Upper-airway cough syndrome
         subjects affected / exposed
    1 / 34 (2.94%)
    1 / 37 (2.70%)
    2 / 61 (3.28%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    2 / 37 (5.41%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    1
    2
    1
    0
    2
    0
    0
    Laryngospasm
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    1
    Nasal congestion
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    1 / 18 (5.56%)
    1 / 29 (3.45%)
    4 / 37 (10.81%)
    1 / 30 (3.33%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    1
    1
    1
    4
    1
    1
    Oropharyngeal cobble stone mucosa
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    1
    Rhinorrhoea
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    3 / 61 (4.92%)
    2 / 18 (11.11%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    1 / 30 (3.33%)
    2 / 14 (14.29%)
         occurrences all number
    0
    0
    4
    2
    0
    2
    1
    3
    Productive cough
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    0
    0
    Throat irritation
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    0
    Throat tightness
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Psychiatric disorders
    Fear of injection
         subjects affected / exposed
    2 / 34 (5.88%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    1 / 30 (3.33%)
    0 / 14 (0.00%)
         occurrences all number
    9
    0
    0
    0
    0
    0
    1
    0
    Insomnia
         subjects affected / exposed
    2 / 34 (5.88%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    2 / 29 (6.90%)
    0 / 37 (0.00%)
    1 / 30 (3.33%)
    1 / 14 (7.14%)
         occurrences all number
    2
    0
    0
    0
    2
    0
    1
    1
    Enuresis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Encopresis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Attention deficit hyperactivity disorder
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    3 / 61 (4.92%)
    0 / 18 (0.00%)
    1 / 29 (3.45%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    3
    0
    1
    1
    0
    0
    Investigations
    Hepatic enzyme increased
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Blood potassium increased
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Aspartate aminotransferase increased
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Alanine aminotransferase increased
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Neutrophil count decreased
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Blood alkaline phosphatase increased
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Blood parathyroid hormone increased
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    0
    0
    0
    Serum ferritin decreased
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Injury, poisoning and procedural complications
    Arthropod bite
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    2 / 37 (5.41%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    2
    0
    1
    0
    2
    0
    0
    Ligament sprain
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    1 / 29 (3.45%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    1
    0
    2
    0
    1
    0
    0
    1
    Arthropod sting
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    2 / 61 (3.28%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    1
    2
    0
    0
    1
    0
    1
    Face injury
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    2 / 61 (3.28%)
    0 / 18 (0.00%)
    2 / 29 (6.90%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    2
    0
    2
    0
    0
    0
    Wrist fracture
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    1 / 29 (3.45%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    1
    1
    0
    0
    0
    Sunburn
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    0
    Gas poisoning
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Nasal injury
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Foot fracture
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    0
    0
    Animal bite
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    1 / 29 (3.45%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    1
    0
    0
    0
    Hand fracture
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Joint injury
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    2 / 61 (3.28%)
    0 / 18 (0.00%)
    1 / 29 (3.45%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    2
    0
    1
    1
    0
    0
    Limb injury
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    2 / 37 (5.41%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    2
    0
    0
    Ligament rupture
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    1
    0
    0
    0
    0
    0
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    2 / 34 (5.88%)
    1 / 37 (2.70%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    1 / 30 (3.33%)
    0 / 14 (0.00%)
         occurrences all number
    2
    1
    1
    0
    0
    0
    2
    0
    Headache
         subjects affected / exposed
    1 / 34 (2.94%)
    2 / 37 (5.41%)
    6 / 61 (9.84%)
    4 / 18 (22.22%)
    3 / 29 (10.34%)
    4 / 37 (10.81%)
    4 / 30 (13.33%)
    0 / 14 (0.00%)
         occurrences all number
    1
    2
    9
    4
    5
    4
    5
    0
    Lethargy
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Ear and labyrinth disorders
    Otorrhoea
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Ear pain
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    1
    0
    0
    Motion sickness
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    3 / 61 (4.92%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    5
    0
    3
    0
    0
    0
    0
    0
    Eye disorders
    Eye swelling
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    3 / 29 (10.34%)
    0 / 37 (0.00%)
    2 / 30 (6.67%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    0
    3
    0
    2
    0
    Ocular hyperaemia
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    4 / 29 (13.79%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    0
    7
    0
    0
    0
    Eye pruritus
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    1 / 29 (3.45%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    2
    0
    1
    0
    0
    1
    Dry eye
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    0
    Conjunctivitis allergic
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    1
    Astigmatism
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Gastrointestinal disorders
    Vomiting
         subjects affected / exposed
    6 / 34 (17.65%)
    3 / 37 (8.11%)
    11 / 61 (18.03%)
    2 / 18 (11.11%)
    3 / 29 (10.34%)
    5 / 37 (13.51%)
    1 / 30 (3.33%)
    0 / 14 (0.00%)
         occurrences all number
    15
    7
    24
    2
    6
    7
    1
    0
    Abdominal pain
         subjects affected / exposed
    3 / 34 (8.82%)
    1 / 37 (2.70%)
    3 / 61 (4.92%)
    2 / 18 (11.11%)
    3 / 29 (10.34%)
    4 / 37 (10.81%)
    1 / 30 (3.33%)
    1 / 14 (7.14%)
         occurrences all number
    3
    1
    3
    3
    3
    4
    1
    1
    Constipation
         subjects affected / exposed
    2 / 34 (5.88%)
    2 / 37 (5.41%)
    3 / 61 (4.92%)
    0 / 18 (0.00%)
    2 / 29 (6.90%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    2
    2
    3
    0
    2
    1
    0
    0
    Abdominal pain upper
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    2 / 61 (3.28%)
    0 / 18 (0.00%)
    3 / 29 (10.34%)
    2 / 37 (5.41%)
    2 / 30 (6.67%)
    1 / 14 (7.14%)
         occurrences all number
    0
    2
    2
    0
    3
    2
    2
    1
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    5 / 61 (8.20%)
    1 / 18 (5.56%)
    1 / 29 (3.45%)
    1 / 37 (2.70%)
    2 / 30 (6.67%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    5
    1
    2
    1
    2
    0
    Nausea
         subjects affected / exposed
    0 / 34 (0.00%)
    2 / 37 (5.41%)
    2 / 61 (3.28%)
    2 / 18 (11.11%)
    2 / 29 (6.90%)
    1 / 37 (2.70%)
    3 / 30 (10.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    3
    3
    2
    2
    1
    3
    1
    Diarrhoea
         subjects affected / exposed
    1 / 34 (2.94%)
    2 / 37 (5.41%)
    1 / 61 (1.64%)
    3 / 18 (16.67%)
    3 / 29 (10.34%)
    3 / 37 (8.11%)
    2 / 30 (6.67%)
    1 / 14 (7.14%)
         occurrences all number
    1
    2
    1
    9
    3
    3
    3
    2
    Eosinophilic oesophagitis
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    1 / 29 (3.45%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    2 / 14 (14.29%)
         occurrences all number
    1
    0
    0
    0
    1
    1
    0
    2
    Oral pain
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    1
    Oral discomfort
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Dysphagia
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    2 / 29 (6.90%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    1
    0
    3
    1
    0
    1
    Lip blister
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Dyspepsia
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    2 / 18 (11.11%)
    1 / 29 (3.45%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    2
    1
    0
    0
    0
    Abdominal discomfort
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    0
    Faeces hard
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Flatulence
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    1 / 29 (3.45%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    1
    0
    0
    0
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    2 / 34 (5.88%)
    3 / 37 (8.11%)
    5 / 61 (8.20%)
    2 / 18 (11.11%)
    1 / 29 (3.45%)
    4 / 37 (10.81%)
    3 / 30 (10.00%)
    2 / 14 (14.29%)
         occurrences all number
    2
    4
    5
    4
    2
    7
    3
    4
    Eczema
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    3 / 61 (4.92%)
    2 / 18 (11.11%)
    2 / 29 (6.90%)
    0 / 37 (0.00%)
    2 / 30 (6.67%)
    0 / 14 (0.00%)
         occurrences all number
    2
    0
    3
    2
    2
    0
    2
    0
    Urticaria
         subjects affected / exposed
    2 / 34 (5.88%)
    1 / 37 (2.70%)
    2 / 61 (3.28%)
    0 / 18 (0.00%)
    2 / 29 (6.90%)
    1 / 37 (2.70%)
    2 / 30 (6.67%)
    3 / 14 (21.43%)
         occurrences all number
    2
    3
    2
    0
    2
    2
    2
    3
    Dry skin
         subjects affected / exposed
    2 / 34 (5.88%)
    1 / 37 (2.70%)
    3 / 61 (4.92%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    1 / 30 (3.33%)
    0 / 14 (0.00%)
         occurrences all number
    2
    1
    3
    0
    0
    1
    1
    0
    Rash papular
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    2 / 37 (5.41%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    3
    0
    0
    Dermatitis
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    3 / 61 (4.92%)
    0 / 18 (0.00%)
    1 / 29 (3.45%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    1
    3
    0
    1
    0
    0
    1
    Hand dermatitis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Keratosis pilaris
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    0
    Perioral dermatitis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    1 / 30 (3.33%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    1
    Petechiae
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Pruritus
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    2 / 61 (3.28%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    2
    1
    0
    0
    0
    0
    Skin lesion
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    1 / 29 (3.45%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    2
    0
    0
    0
    Rash erythematous
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    1 / 30 (3.33%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    1
    0
    Erythema
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    2 / 61 (3.28%)
    0 / 18 (0.00%)
    1 / 29 (3.45%)
    1 / 37 (2.70%)
    1 / 30 (3.33%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    2
    0
    1
    1
    1
    0
    Macule
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    2 / 61 (3.28%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    0
    0
    0
    Rash macular
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Acne
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Dermatitis contact
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    2 / 61 (3.28%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    1
    0
    0
    Musculoskeletal and connective tissue disorders
    Tendon pain
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Musculoskeletal discomfort
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Pain in extremity
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    4 / 61 (6.56%)
    3 / 18 (16.67%)
    0 / 29 (0.00%)
    2 / 37 (5.41%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    1
    0
    4
    3
    0
    3
    0
    1
    Arthralgia
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    2 / 61 (3.28%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    3
    2
    0
    1
    0
    0
    Back pain
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    3 / 61 (4.92%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    3
    0
    0
    0
    0
    0
    Myalgia
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    2 / 29 (6.90%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    4
    0
    0
    0
    Infections and infestations
    Sinusitis
         subjects affected / exposed
    3 / 34 (8.82%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    1 / 18 (5.56%)
    1 / 29 (3.45%)
    0 / 37 (0.00%)
    1 / 30 (3.33%)
    1 / 14 (7.14%)
         occurrences all number
    3
    0
    1
    1
    1
    0
    1
    1
    Upper respiratory tract infection
         subjects affected / exposed
    3 / 34 (8.82%)
    0 / 37 (0.00%)
    8 / 61 (13.11%)
    1 / 18 (5.56%)
    8 / 29 (27.59%)
    2 / 37 (5.41%)
    1 / 30 (3.33%)
    2 / 14 (14.29%)
         occurrences all number
    3
    0
    8
    1
    9
    2
    1
    2
    Ear infection
         subjects affected / exposed
    2 / 34 (5.88%)
    0 / 37 (0.00%)
    5 / 61 (8.20%)
    1 / 18 (5.56%)
    1 / 29 (3.45%)
    2 / 37 (5.41%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    3
    0
    5
    1
    1
    2
    0
    1
    Molluscum contagiosum
         subjects affected / exposed
    2 / 34 (5.88%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    2
    0
    1
    0
    0
    0
    0
    0
    COVID-19
         subjects affected / exposed
    0 / 34 (0.00%)
    6 / 37 (16.22%)
    5 / 61 (8.20%)
    6 / 18 (33.33%)
    7 / 29 (24.14%)
    11 / 37 (29.73%)
    9 / 30 (30.00%)
    3 / 14 (21.43%)
         occurrences all number
    0
    6
    6
    7
    7
    11
    9
    3
    Viral upper respiratory tract infection
         subjects affected / exposed
    2 / 34 (5.88%)
    0 / 37 (0.00%)
    3 / 61 (4.92%)
    1 / 18 (5.56%)
    4 / 29 (13.79%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    2
    0
    4
    1
    4
    1
    0
    0
    Gastroenteritis viral
         subjects affected / exposed
    1 / 34 (2.94%)
    4 / 37 (10.81%)
    5 / 61 (8.20%)
    1 / 18 (5.56%)
    1 / 29 (3.45%)
    2 / 37 (5.41%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    4
    7
    1
    1
    2
    0
    0
    Nasopharyngitis
         subjects affected / exposed
    2 / 34 (5.88%)
    2 / 37 (5.41%)
    4 / 61 (6.56%)
    1 / 18 (5.56%)
    1 / 29 (3.45%)
    3 / 37 (8.11%)
    1 / 30 (3.33%)
    0 / 14 (0.00%)
         occurrences all number
    2
    2
    4
    1
    1
    6
    1
    0
    Respiratory tract infection viral
         subjects affected / exposed
    1 / 34 (2.94%)
    1 / 37 (2.70%)
    2 / 61 (3.28%)
    1 / 18 (5.56%)
    1 / 29 (3.45%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    2
    1
    2
    3
    1
    1
    0
    1
    Hordeolum
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 37 (0.00%)
    2 / 61 (3.28%)
    0 / 18 (0.00%)
    1 / 29 (3.45%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    4
    0
    3
    0
    1
    0
    0
    3
    Beta haemolytic streptococcal infection
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Conjunctivitis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    4 / 61 (6.56%)
    2 / 18 (11.11%)
    4 / 29 (13.79%)
    2 / 37 (5.41%)
    1 / 30 (3.33%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    5
    2
    4
    2
    1
    0
    Croup infectious
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    4 / 61 (6.56%)
    1 / 18 (5.56%)
    1 / 29 (3.45%)
    2 / 37 (5.41%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    4
    1
    1
    2
    0
    0
    Ear infection viral
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Influenza
         subjects affected / exposed
    0 / 34 (0.00%)
    1 / 37 (2.70%)
    3 / 61 (4.92%)
    1 / 18 (5.56%)
    4 / 29 (13.79%)
    4 / 37 (10.81%)
    0 / 30 (0.00%)
    4 / 14 (28.57%)
         occurrences all number
    0
    1
    3
    1
    4
    4
    0
    4
    Gastrointestinal viral infection
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    1 / 18 (5.56%)
    2 / 29 (6.90%)
    1 / 37 (2.70%)
    1 / 30 (3.33%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    1
    1
    2
    1
    1
    1
    Groin infection
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Impetigo
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Eye infection
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    2 / 29 (6.90%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    0
    0
    Otitis media
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    2 / 61 (3.28%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    3 / 37 (8.11%)
    1 / 30 (3.33%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    2
    1
    0
    3
    1
    0
    Pharyngitis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    2 / 61 (3.28%)
    1 / 18 (5.56%)
    1 / 29 (3.45%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    4
    1
    1
    0
    0
    0
    Pharyngitis streptococcal
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    13 / 61 (21.31%)
    1 / 18 (5.56%)
    2 / 29 (6.90%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    2 / 14 (14.29%)
         occurrences all number
    0
    0
    15
    2
    2
    0
    0
    2
    Urinary tract infection
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    2 / 37 (5.41%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    0
    0
    Stoma site infection
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Tonsillitis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Rhinitis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    2 / 18 (11.11%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    3
    0
    0
    0
    0
    Viral infection
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Pneumonia
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    2 / 37 (5.41%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    2
    0
    0
    Paronychia
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    1 / 61 (1.64%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Gastroenteritis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    2 / 61 (3.28%)
    0 / 18 (0.00%)
    1 / 29 (3.45%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    2
    0
    1
    1
    0
    0
    Cellulitis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    2 / 61 (3.28%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    1 / 37 (2.70%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    1
    0
    0
    Metabolism and nutrition disorders
    Iron deficiency
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    0 / 18 (0.00%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Decreased appetite
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 37 (0.00%)
    0 / 61 (0.00%)
    1 / 18 (5.56%)
    0 / 29 (0.00%)
    0 / 37 (0.00%)
    0 / 30 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    07 Apr 2020
    Added the PEESSv2.0- caregiver version questionnaire as a secondary endpoint; Changed the PESQ-Caregiver and PESQ-Patient questionnaires to secondary endpoints; Clarifications; Added endpoints; Updated inclusion criteria
    18 Nov 2020
    Added additional treatment arm to evaluate a lower exposure of dupilumab; clariifications and updated language.
    13 Jun 2021
    Included an exit interview; added symptom/sign-free days based on the PESQ-P or PESQ-C as a secondary endpoint
    03 Aug 2022
    Added long-term extension period; Clarifications and editorial corrections

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    14May2024 - All participants met criteria defined in the protocol as reasons for treatment completion prior to reaching week 160. The study was not ended prematurely due to safety reasons.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 13:50:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA